PC
APLS

Pier Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Pier Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-76,066
Closed -$5.02M – 116
2023
Q1 		$5.02M Buy
76,066
+849
+1% +$49K 0.76% 69
2022
Q4 		$3.89M Buy
75,217
+19,833
+36% +$1.05M 0.64% 77
2022
Q3 		$3.78M Sell
55,384
-74,956
-58% -$4.44M 0.65% 75
2022
Q2 		$5.89M Buy
130,340
+132
+0.1% +$6.02K 1.01% 56
2022
Q1 		$6.62M Sell
130,208
-91,693
-41% -$4.05M 0.84% 71
2021
Q4 		$10.5M Buy
221,901
+65,870
+42% +$2.59M 1.11% 44
2021
Q3 		$5.14M Buy
+156,031
New +$8.77M 0.53% 91

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pier Capital's APLS Position: Q2 2023 in Review

Pier Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2023, closing a stake of 76,066 shares — an estimated $5.02M sold.

Pier Capital first reported a position in APLS in Q3 2021 and held it in 7 quarters. The position peaked at $10.5M in Q4 2021. 317 funds tracked by Wall St. Rank hold APLS as of Q2 2023.

  • Pier Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Pier Capital sold 76,066 Apellis Pharmaceuticals shares in Q2 2023, an estimated $5.02M.
  • Pier Capital first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • Pier Capital's Apellis Pharmaceuticals position peaked at $10.5M in Q4 2021.
  • 317 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2023.

Based on Pier Capital's 13F filing for Q2 2023, filed 14 Aug 2023.